BEVERLY, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of certain brain cells following a stroke. PARP is a nuclear enzyme that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and has potential applications for the treatment of cardiovascular conditions, oncology, and inflammatory disorders.
